Seek Ltd Stock
Price
Target price
€8.60
€8.60
1.180%
0.1
1.180%
-
16.07.26 / Stuttgart Stock Exchange
WKN: A0EAC4 / Symbol: SKLTF / Name: Seek / Stock / Professional & Commercial Services / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Seek Ltd Stock
There is an upward development for Seek Ltd compared to yesterday, with an increase of €0.10 (1.180%).
Pros and Cons of Seek Ltd in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Seek Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Seek Ltd | 1.180% | 7.500% | 4.242% | -35.338% | -34.351% | -41.497% | -56.345% |
| ALS Ltd | -1.520% | -1.515% | -5.109% | 32.653% | 4.839% | 91.176% | 67.742% |
| Downer EDI Ltd | 0.000% | 1.293% | -2.893% | 27.027% | 5.856% | 70.290% | 38.235% |
| ABM Industries Inc. | -0.490% | 4.124% | 6.878% | -1.942% | 11.602% | 6.878% | 3.590% |
News
J.B. Hunt Transport Services Q2 Earnings Call Highlights
Key Points
- Interested in J.B. Hunt Transport Services, Inc.? Here are five stocks we like better.
- J.B. Hunt posted sharply better Q2 results, with total revenue up 19% year over year
Phillips Edison & Company Says Grocery-Anchored Demand Is Strong, Deals Active
Key Points
- Interested in Phillips Edison & Company, Inc.? Here are five stocks we like better.
- Demand for grocery-anchored shopping centers remains strong, with Phillips Edison saying
Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%
Caris Life Sciences (NASDAQ:CAI) executives said the company is expanding its commercial reach, product pipeline and biopharma partnerships as it looks to build on recent revenue growth following